Cho HJ*, Yeo DJ*, Yang H, Koo J (2024) Comprehensive Transcriptomic Analysis Reveals Cell-Type-Specific Roles of Human Odorant Receptors in Glioblastoma and the Tumor Microenvironment, Int J Mol Sci., 25(24):13382.

Choi J, Cho HJ* (2024) Comprehensive Transcriptomic Profiling of Diverse Brain Tumor Types Uncovers Complex Structures of the Brain Tumor Microenvironment, Biomedicines, 12:506

Cho HJ*, Yun KH, Shin SJ, Lee YH, Kim SH, Baek W, Han YD, Kim SK, Ryu HJ, Lee J, Cho I, Go H, Ko J, Jung I, Jeon MK, Rha SY, Kim HS (2024) Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial, Nat Commun., 685. 

Lim SH, Cho HJ*, Kim K-M, Lim HY, Kang WK, Lee J, Park YS, Kim HC, Kim ST (2023) Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer, Oncology Research, 31(6):855-866.

Hong JY, Cho HJ*, Yun KH, Lee YH, Kim SH, Baek W, Kim SK, Lee Y, Choi YL, Kwon M, Kim HS, Lee J (2023) Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response, Cancer Research and Treatment, 55(2):671-683

Chung C, Cho HJ*, Lee C, Koo J (2022) Odorant receptors in cancer, BMB Reports, 55(2):72-80

Hong JY, Cho HJ*, Sa JK, Liu X, Ha SY, Lee T, Kim H, Kang W, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Park HC, Kang TW, Rhim H, Lee SJ, Cristescu R, Lee J, Paik YH, Lim HY (2022) Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial, Genome Medicine, 14(1):1.

Cho HJ*, Koo J (2021) Odorant G protein-coupled receptors as potential therapeutic targets for adult diffuse gliomas: a systematic analysis and review, BMB Reports, 54(12):601-607.

Hong JY, Cho HJ*, Kim ST, Park YS, Shin SH, Han IW, Lee J, Heo JS, Park JO (2021) Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer, Therapeutic Advances in Medical Oncology, 13:17588359211038478.

Byeon, S., Cho HJ*, Jang KT, Kwon K, Lee J, Kim ST (2021) Molecular Profiling of Asian Patients with Advanced Melanoma Receiving Check-Point Inhibitor Treatment, ESMO Open, 6 (1): 100002.

Li, C, Cho HJ*, Yamashita D, Abdelrashid M, Chen Q, Bastola S, Chagoya G, et al. (2020) Tumor Edge-to-Core Transition Promotes Malignancy in Primary-to-Recurrent Glioblastoma Progression in a PLAGL1/CD109-Mediated Mechanism, Neuro-Oncology Advances, 2 (1): 1–12.

Lee, MS, Cho HJ*, Hong JY, Lee K, Park SH, Park JO, Park YS, et al. (2020) Clinical and Molecular Distinctions in Patients with Refractory Colon Cancer Who Benefit from Regorafenib Treatment, Therapeutic Advances in Medical Oncology, 12: 1–8.

Sa JK*, Chang N*, Lee HW*, Cho HJ*, Ceccarelli M*, Cerulo L, Yin J, Kim SS, Caruso FP, Lee M, Kim D, Oh YT, Lee Y, Her NG, Min B, Kim HJ, Jeong DE, Kim HM, Kim H, Chung S, Woo HG, Lee J, Kong DS, Seol HJ, Lee JI, Kim J, Park WY, Wang Q, Sulman EP, Heimberger AB, Lim M, Park JB, Iavarone A, Verhaak RGW, Nam DH (2020) Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma, Genome Biol., 21:216

Oh S*, Yeom J*, Cho HJ*, Kim JH, Yoon SJ, Kim H, Sa JK, Ju S, Lee H, Oh MJ, Lee W, Kwon Y, Li H, Choi S, Han JH, Chang JH, Choi E, Kim J, Her NG, Kim SH, Kang SG, Paek E, Nam DH, Lee C, Kim HS (2020) Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities, Nat Commun., 11(1):3288.

Shin K*, Shin H*, Cho HJ*, Kang H, Lee JK, Seo YJ, Shin YJ, Kim D, Koo H, Kong DS, Seol HJ, Lee JI, Lee HW, Nam DH (2020) Sphere-Forming Culture for Expanding Genetically Distinct Patient-Derived Glioma Stem Cells by Cellular Growth Rate Screening, Cancers, 12(3). 

Cho HJ*, Zhao J*, Jung SW*, Ladewig E*, Kong DS*, Suh YL, Lee Y, Kim D, Ahn SH, Bordyuh M, Kang HJ, Sa JK, Seo YJ, Kim ST, Lim DH, Dho YS, Lee JI, Seol HJ, Choi JW, Park WY, Park CK, Rabadan R, Nam DH (2019) Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma, Neuro Oncol, 21(1):47-58.

Kim J*, Lee IH*, Cho HJ*, Park CK*, Jung YS, Kim Y, Nam SH, Kim BS, Johnson MD, Kong DS, Seol HJ, Lee JI, Joo KM, Yoon Y, Park WY, Lee J, Park PJ, Nam DH (2015) Spatiotemporal Evolution of the Primary Glioblastoma Genome, Cancer Cell, 28(3):318-28.